Metabolic profile of first and second generation antipsychotics among Chinese patients

Psychiatry Res. 2011 Feb 28;185(3):456-8. doi: 10.1016/j.psychres.2010.04.050. Epub 2011 Jan 14.

Abstract

The metabolic profiles of Chinese patients treated with second-generation antipsychotic (SGA) medication and first-generation antipsychotic (FGA) medication were compared. The sample comprised 99 patients treated with SGA (risperidone, olanzapine and ziprasidone) and 99 with FGA (chlorpromazine, haloperidol and trifluoperazine) from the outpatient clinic of a teaching hospital in Hong Kong. The most frequent psychiatric diagnosis was schizophrenia, followed by affective disorder and other psychiatric diagnoses. Subjects were measured for body weight, body height, fasting lipid and glucose levels. SGA was associated with higher LDL-cholesterol level than FGA. Individual comparison of different antipsychotics showed that patients on olanzapine had the greatest increases in cholesterol and triglycerides among all antipsychotics. The finding suggested SGA, particularly olanzapine, were associated with more metabolic risk factors than first-generation antipsychotics.

MeSH terms

  • Adult
  • Antipsychotic Agents* / classification
  • Antipsychotic Agents* / metabolism
  • Antipsychotic Agents* / therapeutic use
  • Asian Continental Ancestry Group
  • Body Mass Index
  • Cholesterol / metabolism
  • Female
  • Humans
  • Male
  • Mental Disorders / drug therapy
  • Mental Disorders / metabolism*
  • Middle Aged

Substances

  • Antipsychotic Agents
  • Cholesterol